Sign In
Buy ONCT
$0.527
+0 (+0%)
At Close: Feb 28, 2025
HC Wainwright Sees This Small-Cap Biotech As Undervalued, Underappreciated
11:21am, Monday, 13'th Jun 2022
At the European Hematology Association (EHA) meeting, Oncternal Therapeutics Inc (NASDAQ: ONCT) presented initial preclinical results of Oncternal's ROR1 CAR containing the antigen-binding region
Oncternal Therapeutics: As Phase 2 Study Matures, Data Continues To Improve
12:46pm, Tuesday, 07'th Jun 2022
ONCT already has great data in MCL, but that data further improved as the Phase 2 study matured. I parse some of the results and compare them to previous data from current standard of care ibrutinib.
Hot Penny Stocks to Watch as May Ends
02:41pm, Friday, 27'th May 2022
Here are three penny stocks to add to your watchlist right now The post Hot Penny Stocks to Watch as May Ends appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2022
02:17pm, Tuesday, 10'th May 2022 Benzinga
Upgrades
According to Nomura Instinet, the prior rating for Goodyear Tire & Rubber Co (NASDAQ:GT) was changed from Neutral to Buy. In the first quarter, Goodyear Tire & Rubber showed an EPS of $0.37,
Oncternal Therapeutics, Inc. (ONCT) Q1 2022 Earnings Call Transcript
08:30pm, Friday, 06'th May 2022 The Motley Fool
ONCT earnings call for the period ending March 31, 2022.
Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates
09:55pm, Thursday, 05'th May 2022 Zacks Investment Research
Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of -5.26% and 6.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates
07:34pm, Thursday, 05'th May 2022
Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of -5.26% and 6.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Oncternal Therapeutics, Inc. (ONCT) CEO James Breitmeyer on Q1 2022 Results - Earnings Call Transcript
07:30pm, Thursday, 05'th May 2022
Oncternal Therapeutics, Inc (NASDAQ:ONCT ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants James Breitmeyer – President & Chief Executive Officer Richard Vincent – Chi
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
09:00pm, Monday, 02'nd May 2022 GlobeNewswire Inc.
SAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today anno
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results
09:00pm, Thursday, 28'th Apr 2022 GlobeNewswire Inc.
SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today an
Oncternal Therapeutics (ONCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
07:02pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Oncternal Therapeutics (ONCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Oncternal Therapeutics Deprioritizes Development of ONCT-216 to Focus Resources on Phase 3 Trial for Zilovertamab in the Treatment of Mantle Cell Lymphoma
12:30pm, Wednesday, 13'th Apr 2022 GlobeNewswire Inc.
SAN DIEGO, April 13, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today an
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
09:00pm, Friday, 01'st Apr 2022 GlobeNewswire Inc.
SAN DIEGO, April 01, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today an
Oncternal Therapeutics, Inc. (ONCT) Q4 2021 Earnings Call Transcript
04:00am, Friday, 11'th Mar 2022 The Motley Fool
ONCT earnings call for the period ending December 31, 2021.
Oncternal Therapeutics, Inc. (ONCT) CEO James Breitmeyer on Q4 2021 Results - Earnings Call Transcript
10:28pm, Thursday, 10'th Mar 2022
Oncternal Therapeutics, Inc. (ONCT) CEO James Breitmeyer on Q4 2021 Results - Earnings Call Transcript
